Literature DB >> 30589055

Expression of leukocyte immunoglobulin-like receptor B2 in hepatocellular carcinoma and its clinical significance.

Xinwen Li1, Xiaojuan Wei2, Huirong Xu3, Zuowei Sha3, Aiqin Gao2, Yuping Sun2, Juan Li2, Liyou Xu4.   

Abstract

BACKGROUND: Leukocyte immunoglobulin-like receptor B2 (LILRB2) has recently been considered a promising tumor promoter in human cancers.
MATERIALS AND METHODS: In this study, the expression of LILRB2 was assessed in 82 samples of surgically resected human hepatocellular carcinoma (HCC) tissues using immunohistochemistry (IHC).
RESULTS: LILRB2 was overexpressed in HCC tissues and its expression was positively and significantly correlated with poor prognostic features of HCC patients, including poor cell differentiation, larger primary tumor size, and shorter overall survival. In addition, there was a positive correlation between the expression of LILRB2 and its classical ligand human leukocyte antigen G in human HCC tissues.
CONCLUSION: LILRB2 might play an important role in HCC progression and correlate with poor prognosis of HCC.

Entities:  

Keywords:  Hepatocellular carcinoma; human leukocyte antigen G; leukocyte immunoglobulin-like receptor B2; prognosis

Mesh:

Substances:

Year:  2018        PMID: 30589055     DOI: 10.4103/jcrt.JCRT_542_18

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

1.  Combined screening analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma.

Authors:  Jisen Cao; Ruiqiang Zhang; Ye Zhang; Yijun Wang
Journal:  J Gastrointest Oncol       Date:  2022-02

2.  Diagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma.

Authors:  Jiyuan Zhou; Wanna Yang; Shu Zhang; Xuanqiu He; Jiatian Lin; Tao Zhou; Yaqin Li; Guiqiang Wang; Junhui Chen
Journal:  Cancer Manag Res       Date:  2019-07-29       Impact factor: 3.989

3.  Overexpressed immunoglobulin-like transcript (ILT) 4 in lung adenocarcinoma is correlated with immunosuppressive T cell subset infiltration and poor patient outcomes.

Authors:  Qing Li; Juan Li; Shuyun Wang; Jingnan Wang; Xiaozheng Chen; Dongmei Zhou; Yuying Fang; Aiqin Gao; Yuping Sun
Journal:  Biomark Res       Date:  2020-04-29

4.  ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.

Authors:  Xiaozheng Chen; Aiqin Gao; Fang Zhang; Zijiang Yang; Shuyun Wang; Yuying Fang; Juan Li; Jingnan Wang; Wenjing Shi; Linlin Wang; Yan Zheng; Yuping Sun
Journal:  Theranostics       Date:  2021-01-19       Impact factor: 11.556

5.  Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.

Authors:  Aiqin Gao; Xia Liu; Wenli Lin; Jingnan Wang; Shuyun Wang; Fusheng Si; Lan Huang; Yangjing Zhao; Yuping Sun; Guangyong Peng
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

6.  Analysis of the expression and prognosis for leukocyte immunoglobulin-like receptor subfamily B in human liver cancer.

Authors:  Jing Fan; Lili Wang; Miao Chen; Jiakang Zhang; Jiayan Li; Fangnan Song; Aidong Gu; Dandan Yin; Yongxiang Yi
Journal:  World J Surg Oncol       Date:  2022-03-24       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.